Since the introduction of imatinib (IMT), the first commercial tyrosine kinase inhibitor (TKI) for BCR-ABL1, in 2001, there has been a revolution in the treatment of CML, achieving remarkable results [5]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.